A Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of ICP-022 in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orelabrutinib (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Sponsors InnoCare Pharma

Most Recent Events

06 Nov 2019 Results presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
17 Jun 2019 Status changed from recruiting to active, no longer recruiting.
09 Aug 2018 Status changed from not yet recruiting to recruiting.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight